Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
Titel:
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
Auteur:
Yamazaki, K. Yamanaka, T. Shiozawa, M. Manaka, D. Kotaka, M. Gamoh, M. Shiomi, A. Makiyama, A. Munemoto, Y. Rikiyama, T. Fukunaga, M. Ueki, T. Shitara, K. Shinkai, H. Tanida, N. Oki, E. Sunami, E. Ohtsu, A. Maehara, Y. Yoshino, T.